复星医药最新公告：斯鲁利单抗注射液新增适应症获欧盟批准

证券之星06-25

复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液(欧盟商品名：Hetronifly)新增适应症获欧盟委员会批准，本次获批适应症为联合卡铂和白蛋白紫杉醇用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌成人患者的一线治疗。该药品为本集团自主研发的创新型抗PD-1单抗，截至公告日已在中国、欧盟、英国等多国获批上市。本次获批可进一步丰富该药品的临床应用，强化海外市场布局。

以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。

相关 ETF

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2646187927?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-25 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2646187927","market":"hk","top_or_hot":-1,"title":"复星医药最新公告：斯鲁利单抗注射液新增适应症获欧盟批准","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/600196\">复星医药</a>(600196.SH)公告称，公司控股子公司<a href=\"https://laohu8.com/S/02696\">复宏汉霖</a>自主研发的斯鲁利单抗注射液(欧盟商品名：Hetronifly)新增适应症获欧盟委员会批准，本次获批适应症为联合卡铂和白蛋白紫杉醇用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌成人患者的一线治疗。该药品为本集团自主研发的创新型抗PD-1单抗，截至公告日已在中国、欧盟、英国等多国获批上市。本次获批可进一步丰富该药品的临床应用，强化海外市场布局。</p><p>以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。</p><h2>相关 ETF</h2><p><img src=\"https://static.stockstar.com/etf/51031020260625.png\"/><img src=\"https://static.stockstar.com/etf/15936120260625.png\"/><img src=\"https://static.stockstar.com/etf/51201020260625.png\"/><img src=\"https://static.stockstar.com/etf/51608020260625.png\"/></p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药最新公告：斯鲁利单抗注射液新增适应症获欧盟批准</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药最新公告：斯鲁利单抗注射液新增适应症获欧盟批准\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-25 18:00 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026062500033246.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液(欧盟商品名：Hetronifly)新增适应症获欧盟委员会批准，本次获批适应症为联合卡铂和白蛋白紫杉醇用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌成人患者的一线治疗。该药品为本集团自主研发的创新型抗PD-1单抗，截至公告日已在中国、欧盟、英国等多国获批上市。本次获批可进一步丰富该药品的临床应用，强化海外市场...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026062500033246.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02196","symbol_name":"复星医药","start_time":0,"source_url":"https://stock.stockstar.com/RB2026062500033246.shtml","article_id":"2646187927","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2646187927","pubTimestamp":1782381655,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液(欧盟商品名：Hetronifly)新增适应症获欧盟委员会批准，本次获批适应症为联合卡铂和白蛋白紫杉醇用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌成人患者的一线治疗。该药品为本集团自主研发的创新型抗PD-1单抗，截至公告日已在中国、欧盟、英国等多国获批上市。本次获批可进一步丰富该药品的临床应用，强化海外市场布局。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600196":"复星医药","02196":"复星医药","BK0183":"MSCI概念","BK0096":"民营医院","BK0188":"融资融券","BK1191":"制药","BK1515":"抗疫概念","BK1593":"医美概念股","BK0012":"证金概念","BK0196":"行业龙头","BK0239":"医药制造","BK0175":"白马股","BK0060":"抗癌","BK0187":"一线龙头","BK0028":"国家队"},"translate_title":"Fosun Pharma's latest announcement: new indications for Slulizumab injection approved by the EU","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1.5,"FESXmain":1.5,"02196":1.5,"FSXEmain":1.5},"content_text":"复星医药(600196.SH)公告称，公司控股子公司复宏汉霖自主研发的斯鲁利单抗注射液(欧盟商品名：Hetronifly)新增适应症获欧盟委员会批准，本次获批适应症为联合卡铂和白蛋白紫杉醇用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌成人患者的一线治疗。该药品为本集团自主研发的创新型抗PD-1单抗，截至公告日已在中国、欧盟、英国等多国获批上市。本次获批可进一步丰富该药品的临床应用，强化海外市场布局。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。相关 ETF","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2646187927","isCrawlerRequest":true}